Published in Eur Rev Med Pharmacol Sci on April 01, 2011
Therapeutic implications of mesenchymal stem cells in liver injury. J Biomed Biotechnol (2011) 1.02
Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer. Stem Cells Dev (2012) 0.97
Adipose-derived mesenchymal cells for bone regereneration: state of the art. Biomed Res Int (2013) 0.93
Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety. Int Arch Med (2012) 0.82
In vitro differentiation of rat mesenchymal stem cells to hepatocyte lineage. Iran J Basic Med Sci (2015) 0.82
Using mesenchymal stem cells as a therapy for bone regeneration and repairing. Biol Res (2015) 0.77
Effect of Microenvironment on Differentiation of Human Umbilical Cord Mesenchymal Stem Cells into Hepatocytes In Vitro and In Vivo. Biomed Res Int (2016) 0.76
Identification and characterization of mesenchymal-epithelial progenitor-like cells in normal and injured rat liver. Am J Pathol (2014) 0.76
Hypoxic Conditioned Medium From Human Adipose-Derived Stem Cells Promotes Mouse Liver Regeneration Through JAK/STAT3 Signaling. Stem Cells Transl Med (2016) 0.75
Expression of antisense of microRNA-26a-5p in mesenchymal stem cells increases their therapeutic effects against cirrhosis. Am J Transl Res (2017) 0.75
Comparison of the Treatment Efficiency of Bone Marrow-Derived Mesenchymal Stem Cell Transplantation via Tail and Portal Veins in CCl4-Induced Mouse Liver Fibrosis. Stem Cells Int (2015) 0.75
Off-label use of adipose-derived stem cells. Ann Med Surg (Lond) (2017) 0.75
Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther (2014) 2.81
Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation (1998) 2.75
Aneurysmal bone cyst of the mobile spine: report on 41 cases. Spine (Phila Pa 1976) (2001) 2.37
Complications of double balloon enteroscopy: a multicenter survey. Endoscopy (2007) 2.28
Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet (1998) 2.15
Osteoid osteoma. Direct visual identification and intralesional excision of the nidus with minimal removal of bone. J Bone Joint Surg Br (1999) 2.13
Atrophic gastritis as a cause of hyperhomocysteinaemia. Aliment Pharmacol Ther (2004) 2.09
Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2005) 1.78
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther (2006) 1.76
Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther (2002) 1.73
Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci (1998) 1.61
Caudal blockade as alternative therapeutic approach in neonatal arterial thrombosis. Eur J Pediatr (2001) 1.61
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol (2004) 1.59
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther (2003) 1.59
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut (2003) 1.56
Do internal mammary artery side-branches have the potential for haemodynamically significant flow steal? Eur J Cardiothorac Surg (1999) 1.56
Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2005) 1.54
Steal phenomenon from mammary side branches: when does it occur? Ann Thorac Surg (1998) 1.53
Push-and-pull enteroscopy in the small bowel using the double-balloon technique: results of a prospective European multicenter study. Endoscopy (2005) 1.53
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther (2001) 1.52
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant (2014) 1.50
Cirrhotic cardiomyopathy. Dig Liver Dis (2007) 1.49
Minimally invasive percutaneous fixation in the treatment of thoracic and lumbar spine fractures. Eur Spine J (2009) 1.45
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis (2010) 1.45
Balancing utility and need by means of donor-to-recipient matching: a challenging problem. Am J Transplant (2013) 1.43
The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with peripheral artery occlusive disease. Eur J Vasc Endovasc Surg (2002) 1.43
Analgesic, antiulcer, antithrombotic drugs and organ damage: a population-based case-control study. Minerva Med (2015) 1.40
Effects of Lactobacillus GG on genes expression pattern in small bowel mucosa. Dig Liver Dis (2005) 1.39
Bacteroides thetaiotaomicron in the gut: molecular aspects of their interaction. Dig Liver Dis (2007) 1.36
Clinical features, diagnostic and therapeutic approaches to haematogenous vertebral osteomyelitis. Eur Rev Med Pharmacol Sci (2005) 1.29
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther (2000) 1.24
Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol (2001) 1.19
Liver transplantation: the Italian experience. Dig Liver Dis (2002) 1.19
Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther (2005) 1.19
Review article: breath testing for human liver function assessment. Aliment Pharmacol Ther (2002) 1.19
Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther (2007) 1.18
High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2007) 1.17
Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand (1998) 1.16
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther (2000) 1.16
Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol (1997) 1.16
High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis. J Rheumatol (2000) 1.15
Fatty liver and drugs. Eur Rev Med Pharmacol Sci (2005) 1.15
Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther (2015) 1.15
Modular endoprosthetic replacement after total resection of the femur for malignant tumour. Int Orthop (1994) 1.14
High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther (2004) 1.14
Intraepiphyseal resection of the proximal tibia and its impact on lower limb growth. Clin Orthop Relat Res (1999) 1.13
Helicobacter pylori infection and diabetes. Minerva Med (2010) 1.11
Symptomatic vertebral hemangioma: the treatment of 23 cases and a review of the literature. Chir Organi Mov (2002) 1.11
Osteosarcoma of the bones of the foot--an easily misdiagnosed malignant tumor. Mayo Clin Proc (1998) 1.08
Letter: Faecal microbiota transplantation--not a one-size-fits-all approach. Aliment Pharmacol Ther (2014) 1.07
Staging and treatment of osteoblastoma in the mobile spine: a review of 51 cases. Eur Spine J (2012) 1.07
The Italian experience on paediatric liver transplantation: 1988-1999 report. Dig Liver Dis (2002) 1.06
Importance of changes in epithelial cell turnover during Helicobacter pylori infection in gastric carcinogenesis. Gut (1998) 1.06
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther (2004) 1.04
Retracted Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2003) 1.03
Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci (2009) 1.03
Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2005) 1.02
Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis (2008) 1.01
Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther (2005) 1.01
Recurrent spontaneous abortion and intrauterine fetal growth retardation as symptoms of coeliac disease. Lancet (2000) 1.00
High prevalence of celiac disease in psoriasis. Am J Gastroenterol (2003) 1.00
Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol (2001) 0.99
Color Doppler sonography in the diagnosis and monitoring of arterial complications after liver transplantation. J Clin Ultrasound (2000) 0.99
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion (2001) 0.99
Anxiety and depression in adult untreated celiac subjects and in patients affected by inflammatory bowel disease: a personality "trait" or a reactive illness? Hepatogastroenterology (1997) 0.99
A human umbilical cord stem cell rescue therapy in a murine model of toxic liver injury. Dig Liver Dis (2004) 0.98
Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. Dig Liver Dis (2007) 0.98
Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer. Eur Rev Med Pharmacol Sci (2009) 0.98
Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis (2007) 0.98
Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci (2005) 0.97
Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther (2000) 0.96
The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci (2013) 0.95
The K469E polymorphism of the ICAM-1 gene is a risk factor for peripheral arterial occlusive disease. Blood Coagul Fibrinolysis (2002) 0.95
Hepatic steatosis and vascular disease. Eur Rev Med Pharmacol Sci (2005) 0.95
No evidence of hematopoietic stem cell mobilization in patients submitted to hepatectomy or in patients with acute on chronic liver failure. Transplant Proc (2005) 0.95
Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther (2010) 0.94
Idiopathic chronic constipation: pathophysiology, diagnosis and treatment. Hepatogastroenterology (2001) 0.94
Clinical and pathologic features of hepatocellular carcinoma in young and older Italian patients. Cancer (1996) 0.94
Early atherosclerosis in patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci (2006) 0.94
Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. J Hepatol (1995) 0.93
Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig Liver Dis (2005) 0.93
Extraintestinal pathology associated with Helicobacter infection. Eur J Gastroenterol Hepatol (1997) 0.92
Nutritional aspects of Helicobacter pylori infection. Minerva Gastroenterol Dietol (2011) 0.92
Levothyroxine absorption in health and disease, and new therapeutic perspectives. Eur Rev Med Pharmacol Sci (2014) 0.91
Mesenchymal stromal cells multipotency and plasticity: induction toward the hepatic lineage. Eur Rev Med Pharmacol Sci (2009) 0.91
Bacterial bloodstream infections in liver transplantation: etiologic agents and antimicrobial susceptibility profiles. Transplant Proc (2012) 0.91